Vascular endothelial growth factor inhibitors, led by bevacizumab, are considered the cornerstone of the therapy in metastatic colorectal carcinoma. We present the case of a patient with metastatic colorectal cancer who experienced rapid tumour growth with liver broad invasion after the withdrawal of an antivascular endothelial growth factor therapy, aflibercept. The rebound effect caused by the residual tumour inducing a regrowth after an initial controlled disease has already been stressed in mice and metastatic colorectal cancer patients following bevacizumab interruption. The use of liver volume evaluation was consistent with the Response Evaluation Criteria in Solid Tumours 1.1 criteria evaluation and might be a useful tool in patients with more than a half liver invasion. We describe for the first time the case of a major liver disease progression, confirmed by Response Evaluation Criteria in Solid Tumours 1.1 criteria and liver volume evaluation, after an antiangiogenic interruption in second line.
aGastroenterology and Digestive Oncology Unit, AP-HP
bDepartment of Radiology, Cochin University Hospital
cU1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Correspondence to Romain Coriat, MD, PhD, Department of Gastroenterology and Digestive Oncology, Cochin University Hospital, Université Paris Descartes, AP-HP, 27, rue du faubourg Saint Jacques, 75014 Paris, France Tel: +33 1 58 41 19 52; fax: +33 1 58 41 41 55; e-mail: firstname.lastname@example.org
Received April 25, 2017
Accepted June 13, 2017